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40 word summary 
Neonatal BCG vaccination results in a decreased proportion of infants mounting an IFN-g 
response to heterologous stimulation at 7 months of age. Both sex and maternal BCG 
vaccination status influenced the effect of BCG vaccination on heterologous cytokine 
responses.  
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Abstract  
 
Background. Bacille Calmette-Guérin (BCG) vaccination has beneficial non-specific 
(heterologous) effects that protect against non-mycobacterial infections. We have previously 
reported that BCG vaccination at birth alters in vitro cytokine responses to heterologous 
stimulants in the neonatal period. This study investigated heterologous responses in 167 
infants in the same trial seven months after randomisation.  
Methods. A whole blood assay was used to interrogate in vitro cytokine responses to 
heterologous stimulants (killed pathogens) and Toll-like receptor (TLR) ligands. 
Results. Compared to BCG-naïve infants, BCG-vaccinated infants had increased production 
of MIG and IFN-g in response to mycobacterial stimulation and decreased production of IFN-
g in response to heterologous stimulation. Reduced IFN-g responses to heterologous 
stimulants and TLR ligands were attributable to a decrease in the proportion of infants who 
mounted a detectable IFN-g response. BCG-vaccinated infants also had increased production 
of MIG and IL-8, and decreased production of IL-10, MIP-1α and MIP-1ß, the pattern of 
which varied by stimulant. IL-1Ra responses following TLR1/2 (Pam3CYSK4) stimulation 
were increased in BCG-vaccinated infants. Both sex and maternal BCG vaccination status 
influenced the effect of neonatal BCG vaccination.  
Conclusions. BCG vaccination leads to changes in IFN-g responsiveness to heterologous 
stimulation. BCG-induced changes in other cytokine responses to heterologous stimulation 
varies by pathogen. 
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Introduction 
Bacille Calmette-Guérin (BCG) vaccination at birth is associated with decreased mortality in 
infants [1, 2]. This is proposed to be due to heterologous (‘non-specific’) protection against 
early-life infections, an effect presumed to result from the immunomodulatory properties of 
BCG [3, 4]. The beneficial non-specific effects of BCG vaccine persist beyond the neonatal 
period. BCG vaccination is associated with reduced incidence of lower respiratory tract 
infections in childhood and sepsis in the first year of life [5, 6] and protection against eczema 
in infants with an atopic disposition [7]. Maternal BCG, delivery method and gestational age 
have been reported to modify the non-specific effects of BCG [8, 9]. 
 
The mechanisms underlying the beneficial heterologous effects of BCG vaccination remain 
unclear [10]. We have previously shown that in vitro cytokine responses to heterologous 
stimulants differs between BCG-vaccinated and BCG-naïve neonates [11]. The longer term 
heterologous immunological effects induced by neonatal BCG are poorly defined but are 
likely to be different. Maturational changes mean the immune response in infancy is different 
to that of neonates [12-14]. In addition, a central hypothesis in the literature on the non-
specific effects of vaccination is that live vaccines confer protection against all-cause 
mortality, which is negated by subsequent non-live vaccines in the first six months of life 
[15]. In the current study, we report the effect of neonatal BCG vaccination on heterologous 
cytokine responses in infants from a randomised controlled trial at seven months of age.  
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Methods  
Participants were a subset of infants recruited from The Melbourne Infant Study: BCG for the 
prevention of allergy and infection (MIS BAIR) in which neonates were randomised to 
vaccination with BCG-Denmark 0.05 mL intradermally or no BCG vaccination (Clinical 
trials registration NCT01906853). The inclusion and exclusion criteria for MIS BAIR are 
described elsewhere [16]. MIS BAIR participants were invited to attend a 7-month study visit 
to provide a blood sample. All particpants with a blood sample from December 2014 to April 
2016 were recruited to this sub-study. Inclusion criteria for cytokine analysis were: (i) 
sufficient blood for all stimulants or (ii) participant provided sample in previous study [11]. 
Exclusion criteria were: (i) fever in the previous 24 hours; (ii) chronic illness (iii) less than 
two doses of the routine scheduled vaccines; (iv) any vaccination within the last 7 days; and 
(iv) any blood products since birth (Figure 1).  
 
Venous blood was collected and in vitro stimulation assays were done as described 
previously [17]. Briefly, whole blood, diluted 1:1 with RPMI-1640 medium (GlutaMAX™ 
Supplement, HEPES, Gibco, Life Technologies), was stimulated at 37°C (5% CO2: air) for 
20 (± 2) hours with RPMI alone (unstimulated control), BCG-Denmark (Serum Statens 
Institute, Denmark) 75 μg/mL, killed Mycobacterium tuberculosis 1.0 x 106 CFU/mL, 
Escherichia coli 1.0 x 106 CFU/mL, Haemophilus influenzae type B 1.0 x 106 CFU/mL, 
Staphylococcus aureus 1.0 x 107 CFU/mL, Streptococcus pyogenes (GAS) 1.0 x 107 
CFU/mL, Streptococcus pneumoniae serotype 15C (non-vaccine serotype) 1.0 x 107 
CFU/mL, Listeria monocytogenes 1.0 x 107 CFU/mL, Candida albicans 1.0 x 106 CFU/mL, 
and the Toll-like receptor (TLR) ligands lipopolysaccharide (LPS; TLR 4 agonist) 100 
ng/mL, resiquimod (R848; TLR 7/8) 3.5 μg/mL, peptidoglycan (PEPG; TLR 2/4) 10 μg/mL 
and (S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-
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Lys4OH,trihydrochloride (Pam3CSK4; TLR 1/2) 1 μg/mL; all from InvivoGen. When 
insufficient blood was available for all stimulations, a pre-determined priority order was 
used. The following cytokines were measured in supernatants using an xMAP Luminex 200 
Analyser as described previously: IFN-g, TNF-α, IL-6, IL-1β, MIF, IL-8 (CXCL8), MIG 
(CXCL9), IP-10 (CXCL10), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1ß (CCL4), IL-10, IL-
1Ra [17]. Study staff were blinded to the BCG-vaccination status of participants.  
 
Statistical analysis was done using Stata version 13.1. Cytokine results below the lower limit 
of detection (LLD) were assigned a value of half the lowest detectable value. There were 14 
values above the upper limit of detection (ULD); these were excluded from the analysis. 
Proportions of detectable values for each cytokine are shown in Supplementary Table 1.  
 
Prior to analysis, all cytokine data were log transformed. Regression analyses, with the log 
transformed value of the unstimulated cytokine values as a covariate, was used to determine 
the effect of (i) BCG vaccination, (ii) maternal BCG vaccination status and (iii) infant’s sex 
on cytokine production in response to each stimulant. This approach was used in all 
regression analyses to account for variability in unstimulated samples and avoids the need for 
nil subtraction. For cytokine/stimulant pairs with normally distributed data (Supplementary 
Figure 1), linear regression was used and results presented as geometric mean ratios (GMR) 
with 95% confidence intervals. For cytokine/stimulant pairs with non-normally distributed 
data (Supplementary Figure 1), quantile regression was used and results presented as 
differences in the medians with 95% confidence intervals.  
 
Subgroup analysis (sex and maternal BCG vaccination status) was done when there was 
statistical evidence of an interaction between BCG vaccination and the subgroup variable, as 
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determined by interaction analysis (Supplementary Table 4). Given the smaller numbers of 
participants in sub-group analyses, quantile regression was used, with bootstrapping as 
required.  
 
Multivariable analysis was done to assess the effect of sex, delivery method, age at infant 
BCG vaccination (less than or greater than 48 hours of life), maternal BCG vaccination 
status, age at blood sample and the number of doses of routine vaccinations received. 
Multivariable analyses, with the unstimulated values as a covariate, were done using linear or 
quantile regression as per the corresponding cytokine/stimulant pair in the primary univariate 
analysis.  
 
For cytokines that showed a dichotomous response, participants were classified according to 
whether cytokine concentrations in the stimulated supernatants were above (‘responders’) or 
below (‘non-responders’) the LLD. Fisher’s exact test was used to compare the proportion of 
‘responders’ between BCG-vaccinated and BCG-naïve participants. To assess the 
contribution of this observation to the results of the primary analysis, a sensitivity analyses 
was done for the effect of BCG vaccination when ‘non-responders’ were excluded. 
 
The study was approved by the research ethics committees of the Royal Children’s Hospital 
(HREC 33025) and the Mercy Hospital for Women (HREC R12/28).  
 
Results 
Demographic features of participants were similar between BCG-vacccinated and BCG-naïve 
participants (Table 1). In unstimulated samples, BCG-vaccinated infants had lower overall 
cytokine concentrations (particularly IL-10, MIF, IP-10 and IL-8) compared with BCG-naïve 
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infants (Table 2). In response to all stimulants, there was marked inter-individual variability 
in cytokine production (Supplementary Figure 1). For IFN-g, IP-10, IL-1Ra and IL-1ß, there 
was evidence of dichotomous responses, i.e. participants who did or did not mount a 
measurable cytokine response following stimulation.  
 
In response to the ‘specific’ mycobacterial antigens BCG and M. tuberculosis, BCG-
vaccinated infants had higher production of IFN-g and MIG compared to BCG-naïve infants, 
and also higher TNF-a and IL-6 following stimulation with BCG (Figure 2, Supplementary 
Table 1). In response to heterologous stimulation with the Gram-positive bacteria S. pyogenes 
and S. aureus, BCG-vaccinated infants had differential production of chemokines including 
MIF, MIG and MIP-1b. Chemokine production in response to stimulation with the 
intracellular pathogens (L. monocytogenes and C. albicans) was also altered in BCG-
vaccinated infants (Figure 2, Supplementary Table 1). In response to stimulation with the 
Gram-negative bacteria E. coli and H. influenzae, and the TLR agonist LPS, BCG-vaccinated 
infants had decreased IFN-g responses and increased IL-8 response compared to BCG-naïve 
infants. In response to stimulation with TLR agonists Pam3CYSK4 (TLR1/2) and PEPG 
(TLR2), BCG-vaccinated infants had increased IL-1Ra production and decreased IFN-g 
production respectively (Figure 2, Supplementary Table 1).  
 
There was a dichotomous IFN-g response to all stimulants aside from R848, with a distinct 
separation between ‘responders’ and ‘non-responders’. For the ‘specific’ mycobacterial 
antigens, BCG and M. tuberculosis, there was a higher proportion of IFN-g responders in the 
BCG-vaccinated group compared to the BCG-naïve group (Figure 3, Supplementary Table 
2). Conversely, for the heterologous stimulants, the proportion of IFN-g responders was 
significantly lower in BCG-vaccinated infants for all stimulants with the exception of S. 
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pneumoniae (Figure 3, Supplementary Table 2). IP-10, IL-1Ra and IL-1b responses showed a 
similar pattern; however, differences in the proportion of responders were not statistically 
significant between BCG-vaccinated and BCG-naïve infants (Supplementary Table 2).  
 
A sensitivity analysis done after removal of all non-responders showed no significant 
difference in IFN-g responses to heterologous stimulants between BCG-vaccinated and BCG-
naïve infants, revealing that the observed difference in IFN-g GMRs was attributable to the 
change in proportion of ‘responders’(Supplementary Table 3). In contrast, the difference in 
the specific IFN-g response to in vitro BCG stimulation between BCG-vaccinated and BCG-
naïve infants was still observed. 
 
Infants’ sex also independently influenced cytokine responses. Compared with girls, boys had 
increased production of both MCP-1 and MIP-1b in response to almost all stimulants 
(Supplementary Table 1 & Supplementary Figure 2). Boys also had increased production of 
IFN-g in response to stimulation with BCG, E. coli, H. influenzae and PEPG, and TNF-a in 
response to most stimulants, particularly E. coli, H. influenzae, LPS and R848 
(Supplementary Table 1 & Supplementary Figure 2). MIG production was also higher in 
boys following stimulation with E. coli. Conversely, boys had decreased production of IL-
1Ra in response to C. albicans and IL-1b in response to L. monocytogenes, and in response to 
Pam3CYSK4 (Supplementary Table 1 & Supplementary Figure 2).  
 
A significant interaction between sex and infant BCG vaccination was seen for multiple 
cytokine/stimulant pairs but most consistently for production of IL-6 and IL-1b 
(Supplementary Table 4). Subgroup analyses of the effect of BCG-vaccination in boys and 
girls separately showed that, compared to BCG-naïve girls, BCG-vaccinated girls had 
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increased pro-inflammatory cytokine production: (a) IL-6 in response to E. coli, H. 
influenzae, LPS and R848 and (b) IL-1b in response to S. pneumoniae (Figure 4, panel a and 
b), and an increase in the anti-inflammatory cytokine IL-1Ra in response to Pam3CYSK4 
(Figure 4, panel c). Overall, compared to BCG-naïve boys, BCG-vaccinated boys had lower 
cytokine production for all cytokine/stimulant pairs when there was an interaction between 
infant BCG vaccination and sex. This was statistically significant for IL-1b/E. coli, IFN-
g/Pam3CYSK4 and TNF-a/C. albicans responses (Figure 4, panel a-c).  
 
Maternal BCG vaccination status independently influenced cytokine responses to 
heterologous stimulants and TLR ligands. Compared to infants of mothers who had not had 
BCG vaccination, infants of mothers who were BCG-vaccinated had increased IFN-g 
production in response to stimulation with M. tuberculosis, decreased IFN-g in response to 
PEPG (TLR2/4); decreased TNF-a in response to BCG, E. coli, H. influenzae, PEPG 
(TLR2/4), LPS (TLR4) and R848 (TLR7/8); decreased IL-1Ra in response to H. influenzae; 
decreased MCP-1 in response to S. pneumoniae and S. pyogenes, decreased IP-10 in response 
to L. monocytogenes, decreased MIP-1ß in response to E. coli and S. pneumoniae 
(Supplementary Table 1 and Supplementary Figure 3).  
 
A significant interaction between maternal BCG vaccination and infant BCG vaccination was 
seen for MIG/E. coli, IL-10/BCG and IFN-g/S. pneumoniae cytokine/stimulant pairs 
(Supplementary Table 4). Separate analyses of the effect of BCG in infants of BCG-
vaccinated mothers and infants of BCG-naïve mothers showed that in the former there was 
lower production of MIG in response to E. coli and IFN-g in response to S. pneumoniae, 
whereas, BCG vaccination had no effect on this response in infants of BCG-naïve mothers 
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(Figure 4, panel d). Conversely, infants of BCG-vaccinated mothers had higher production of 
IL-10 in response to stimulation with BCG (Figure 4, panel d).  
 
Multivariable analyses were done to evaluate the potential confounding effect of sex, 
maternal BCG vaccination status, mode of delivery, age at BCG vaccination, age at blood 
draw, and number of routine vaccination doses received (Supplementary Table 5). Covariate 
analysis with these variables did not reveal any meaningful effect on the primary analysis, 
thus excluding confounding by these variables.  
 
Discussion 
We previously reported that BCG vaccination at birth led to decreased production of IL-1ra, 
IL-6, MCP-1, MIP-1a and MIP-1b in response to heterologous stimulants and TLR ligands 
in the neonatal period (7 days post after randomisation) [17]. This study extends these 
findings to show that BCG-induced changes in cytokine expression following heterologous 
stimulation are detectable at 7 months of age, characterised by decreased IFN-g 
responsiveness in BCG-vaccinated infants. 
 
Our finding that BCG vaccination was associated with an increase in IFN-g and pro-
inflammatory cytokines (IL-6, IL-1b and TNF-a) in response to mycobacterial antigens 
(BCG and M. tuberculosis) is consistent with prior studies [13, 14, 18-20]. Furthermore, our 
finding that two-thirds of BCG-naïve infants produced IFN-g in response to in vitro 
stimulation with BCG supports our previous finding of a role for NK cells and 
unconventional T-cells in early IFN-g responses to BCG [21]. Our main finding that neonatal 
BCG vaccination is associated with a decrease in the proportion of infants who produce IFN-
g in response to heterologous stimulants has not previously been reported.  
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Nissen et al. reported that, in Danish infants at 12 months of age, BCG vaccination did not 
lead to differential IFN-g production either in response to ex vivo heterologous bacterial (E. 
coli, S. pneumoniae, C. albicans) or LPS stimulation [22]. However, in that study 
approximately half of the BCG-vaccinated participants did not have a specific IFN-g response 
to in vitro BCG stimulation. Smith et al. also assessed the effects of BCG on in vitro 
heterologous cytokine responses in infants, although BCG was given at 6 weeks of age [23]. 
As in our study, BCG-vaccinated infants had an increase in M. tuberculosis lysate-induced 
IFN-g response. Although there was no significant difference between BCG-vaccinated and 
BCG-naïve infants in IFN-g production following E. coli, S. aureus, C. albicans, LPS or 
Pam3CYSK4 stimulation, fold-change analysis showed decreased LPS-induced IFN-g 
responses in BCG-vaccinated infants, an effect which did not reach statistical significance 
given the small sample size. 
 
Compared to BCG-naïve infants, BCG-vaccinated infants in our study showed a distinctive 
pattern of differential chemokine production which varied between biologically-related 
stimulants. Specifically, in response to mycobacterial, Gram-positive and intracellular 
heterologous stimulants, chemokine production in BCG-vaccinated infants was characterised 
by increased production of MIG and a concomitant decrease in MIP-1a and MIP-1b. MIG is 
produced by activated monocytes and is the primary chemoattractant for T-helper type 1 
cells, which are central to the IFN-g-dependent pro-inflammatory response to intracellular 
bacteria and parasites, and has been recently reported to represent a marker of trained 
immunity after BCG vaccination [24]. In response to Gram-negative bacteria and LPS, BCG-
vaccinated infants had increased IL-8 production. IL-8 is central in the innate response to 
bacterial infection by promoting neutrophil chemotaxis and macrophage activation. Smith et 
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al reported that, as in our study, BCG-vaccinated infants had significantly higher IL-8 
production following stimulation with LPS compared to BCG-naïve infants [23]. It remains 
to be seen whether variable ‘pathogen-specific’ in vitro patterns of innate immune response 
following BCG-vaccination correlate with clinical protection.  
 
For the majority of heterologous stimulants, IFN-g responses in our study were characterised 
by a significantly lower proportion of IFN-g responders in the BCG-vaccinated group, which 
was responsible for the lower IFN-g GMR in these infants compared to BCG-naïve infants. 
Variable production of IFN-g between individuals and between populations is well described 
[13, 20, 25]. This variability in individual IFN-g responsiveness (which may be genetically or 
environmentally determined [26, 27]) is a potential modifier of the response to BCG. In a 
group of BCG-naïve, TST negative, adult volunteers in the Netherlands who received BCG 
vaccination, ‘non-responders’ were classified as individuals with no IFN-g response to PPD 
and expression of CD8+ regulatory T-cells which persisted up to one year post-vaccination 
[28]. Fletcher et al. reported differential immune responses following BCG vaccination in 
infants characterised by differences in monocyte:T-cell ratios and alternatively activated 
macrophage phenotype (M2) [29]. More recently, Walk et al reported two distinct patterns of 
immune response to human malaria challenge in BCG-vaccinated volunteers. A subgroup of 
volunteers with strong monocyte and lymphocyte activation were also characterised by 
increased IFN-g, granzyme-B production and CRP production [30]. This study is the first to 
report significant changes in IFN-g responsiveness in the context of BCG-induced 
heterologous immunity in infants.  
 
IP-10, IL-1Ra and IL-1b were the only other cytokines which had a subgroup of non-
responders. This is notable in light of the functional relationship of these cytokines to IFN-g 
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and their role in the control of inflammation and pathogen persistence following 
mycobacterial infection [31, 32]. The IL-1 signalling axis is central in mediating the response 
to BCG vaccination in the setting of both mycobacterial and heterologous infections, and IL-
1b is a crucial component for the induction of trained immunity[24, 33-35]. However, in our 
study the proportion of IL-1Ra and IL-1b responders was not significantly different between 
BCG-vaccinated and BCG-naïve infants. Moreover, sensitivity analysis confirmed that 
increased IL-1Ra responses following stimulation of TLR 1/2 (Pam3CYSK4) seen in BCG-
vaccinated infants was unaffected by removal of ‘non-responders’ from the analysis.  
 
In our previous study, we found that infant sex influenced the effect of BCG vaccination on 
the production of MIF following heterologous stimulation [17]. In the present study, we 
observed enhanced E. coli, H. influenzae, LPS and R848-induced production of the 
macrophage derived pro-inflammatory cytokines IL-6 and IL-1b in BCG-vaccinated girls (in 
contrast to boys). This is interesting in light of the suggestion that beyond the neonatal 
period, the beneficial effects of BCG vaccination on mortality is stronger in girls [36].  
 
Maternal BCG vaccination status is associated with increased BCG scar formation and 
decreased all-cause mortality in BCG-vaccinated infants [8]. Mawa et al. reported altered 
cytokine responses to TLR ligands, including LPS, in the cord blood of infants of BCG-
vaccinated mothers [37]. Our finding, that infants of BCG-vaccinated mothers had altered 
cytokine production following heterologous stimulation, independent of infant BCG 
vaccination status, raises the possibility that maternal BCG vaccination ‘primes’ the response 
to infant BCG vaccination. Further, an interaction between maternal and infant BCG 
vaccination on IFN-g production in response to S. pneumoniae was also found in our previous 
study; however maternal BCG had the opposite effect at this time point [17]. This finding is 
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particularly intriguing in light of the finding that BCG vaccine protects infants against 
respiratory infections only in infants whose mothers were also BCG-vaccinated [9, 38].  
 
There is longstanding interest in the variability of BCG vaccine efficacy against tuberculosis 
infection in different geographic locations. To date, clinically significant heterologous effects 
of BCG have mainly been documented in African populations [36]. Following BCG 
vaccination, infant cytokine responses to mycobacteria differ between African and European 
populations, however it remains uncertain whether this is due to genetic or environmental 
influences [13, 14, 39]. In this study, the majority of participants were Caucasian precluding 
subgroup analysis by ethnicity. Exposure to environmental mycobacteria and chronic 
helminth infection has been associated with altered BCG-induced IFN-g production in some 
populations [39]. It is unlikely that exposure to infection was a confounder in our study as 
proxy measures of exposure to common childhood infections (attendance at childcare and 
number of children under five years in the household) were similar between groups.  
 
The strengths of this study include its large sample size and the use of samples from 
participants from a randomised controlled trial. The use of a large number of stimulants and 
multiplex cytokine analysis enabled a comprehensive interrogation of the immune response. 
In addition, we used multivariable analysis to identify potential confounders and a highly 
standardised laboratory protocol to reduce variation. Furthermore, we used the unstimulated 
sample as a co-variate to control for inter-individual variability in cytokine responses. A 
sensitivity analysis, excluding the use of unstimulated samples as a co-variate in samples 
where there was an independent effect on the constitutive expression of a cytokine, showed 
this did not lead to overcorrection (data not shown). Our study has several limitations which 
are common to research of this type. Firstly, for some cytokine/stimulant pairs, there were a 
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lower numbers of participants from whom samples were available. However, this is a large 
study and our statistical analysis accounted for the varying distributions of individual 
cytokine/stimulant pair data. Secondly, while we tested for several potential confounders 
selected due to their biological plausibility and previously published data, it is possible there 
are others that may have influenced our findings. Thirdly, there was a risk of type 1 error due 
to multiple comparisons. Statistical correction for multiple comparisons was not done as this 
was an exploratory analysis that aimed to find consistent patterns in BCG-induced alterations 
in cytokine responses. In addition, we have shown all analyses in their entirety to aid 
interpretation of the results in context. Finally, routine vaccines from the Australian 
immunisation schedule differ to those administered in low and middle-income countries.  
 
In summary, at 7 months of age, following neonatal BCG vaccination, infants had lower IFN-
g responses to heterologous stimulants and TLR ligands compared with BCG-naïve infants. 
This results from  a reduction in the proportion of infants who responded by producing IFN-g 
rather than a reduced level of IFN-g production by all participants. This study is the first to 
report divergent IFN-g responses between mycobacterial and heterologous stimulation 
following BCG-vaccination. BCG-vaccination is associated with variable patterns of 
chemokine response depending on the stimulating pathogen. There was a significant 
interaction between both sex and maternal BCG vaccination and neonatal BCG vaccination. 
Relating the immunological effects of BCG observed in in vitro studies with clinical outcome 
should be a priority for future research.   
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Table & Figure Legends 
 
Table 1: Demographic features of the study participants. Routine immunisations: Infanrix 
Hexaä (hepatitis B, diphtheria-tetanus-pertussis, H. influenzae type B, inactivated 
poliovirus), Prevenar 13ä (13-valent pneumococcal vaccine), rotavirus (Rotarixä or 
RotaTeqä). 
 
Figure 1: Flow diagram showing participant inclusion. Table shows number of individual 
stimulations done for each stimulant. 
 
Table 2: Univariate analysis for the effect of neonatal BCG vaccination versus no BCG 
vaccination on unstimulated cytokine levels. Results shown as GMR (95% CI) for normally-
distributed data and difference in medians (95% CI) from non-parametric quantile regression 
for data which was not normally distributed. 
 
Figure 2: The effect of neonatal BCG vaccination versus no BCG vaccination on cytokine 
responses to heterologous stimulants. Significant results p<0.05 are depicted in black. 
GMR>1.0 indicates cytokine levels were higher in BCG-vaccinated infants compared with 
BCG-naïve infants. Data which were not normally distributed were analysed using quantile 
regression and differences in medians (95%CI). As this only applied to IFN-g, to aid 
interpretation, all IFN-g analyses are displayed on stand-alone axes irrespective of the type of 
analysis done.  
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Figure 3: Proportion of BCG-vaccinated and BCG-naïve participants with production of 
IFN-g in response to heterologous stimulation (‘responders’) (Fisher’s exact test). Data for 
R848 not included as IFN-g responses were above the LLD for all participants. 
 
Figure 4: Subgroup analysis for the effect of infant sex and maternal BCG vaccination on in 
vitro cytokine responses. Panels a-c: IL-6 (a), IL-1b (b), and remaining cytokine/stimulant 
pairs (c) with a significant interaction between sex and BCG vaccination. Geometric mean 
ratios (GMR) & 95% confidence limits (CI) are shown for the effect of infant BCG 
vaccination on (i) all study participants; (ii) in girls; (ii) in boys. Panel d): cytokine/stimulant 
pairs with a significant interaction between maternal BCG vaccination and BCG vaccination. 
GMR & 95%CI are shown for the effect of infant BCG vaccination on (i) all study 
participants; (ii) infants whose mothers were BCG-vaccinated; (iii) infants whose mothers 
were BCG-naïve. GMR > 1 indicates cytokine production is higher in BCG-vaccinated 
infants. 
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